Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QGC001 in Essential Hypertension
NCT02322450Phase 2Completed
- Sponsor
- Quantum Genomics
- Start
- Jan 2015
- Primary completion
- Apr 2016
- Modality
- Prodrugs/Conditional Activator Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of firibastat in essential hypertension (2 arms), sponsored by Quantum Genomics. Primary endpoint: 24-hour Ambulatory Blood Pressure Monitoring at 16 weeks. Started Jan 2015; status: completed.
02
Drugs
firibastat
03
Conditions
essential hypertension
Beyond the preview
Go deeper on NCT02322450.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02322450.